Vertaling van "patients with non-valvular atrial fibrillation " (Nederlands → Frans) :

Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews 2005, Issue.
Cochrane Database of Systematic Reviews 2011, Issue 12.

Aguilar MI, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
Search Date February 2009. [http ...]

Bespreking van: van Walraven C, Hart RG, Conolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the Atrial Fibrillation Investigators.
Dunn A. Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrilllation. Evid Based Med 2009; 14:140.

Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
Olesen JB, Lip GYH, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.

Olesen JB, Lip GYH, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.
Lip GYH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.

Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation.
Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Hylek EM, Evans-Molina C, Shea C, Henault LE en Regan S: Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
Hylek EM, Evans-Molina C, Shea C, Henault LE et Regan S: Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.

Garcia D en Hylek E: Stroke prevention in elderly patients with atrial fibrillation.
Garcia D et Hylek E: Stroke prevention in elderly patients with atrial fibrillation.

Naar Camm AJ en Savelieva I. Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat.
D’après Camm AJ et Savelieva I. Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat.

de Denus S, Sanoski CA, Carlsson J et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis.
van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834-40. de Denus S, Sanoski CA, Carlsson J et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis.